Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bone Biologics Corp - warrants (NQ:BBLGW)

5.970 UNCHANGED
Streaming Delayed Price Updated: 11:28 AM EDT, Aug 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bone Biologics Corp - warrants

News headline image
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
Strengthened capital position supports continued advancement of NB1 clinical development, manufacturing readiness and intellectual property initiatives through Q2 2027 
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
News headline image
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash 
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
News headline image
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
Milestone advances commercial and manufacturing readiness ahead of anticipated pivotal study scale-up 
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
News headline image
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance 
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
News headline image
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
Milestone advances manufacturing readiness and supports long-term commercialization strategy 
From BONE BIOLOGICS CORPORATION
Via GlobeNewswire
News headline image
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Announces Closing of $5.0 Million Public Offering
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Announces Pricing of $5.0 Million Public Offering
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Files Patent Application for Bone Regeneration Technology
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Announces 1-for-6 Reverse Stock Split
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
From Bone Biologics
Via Business Wire
News headline image
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
From Bone Biologics Corporation
Via Business Wire
News headline image
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Executives to be Interviewed in a “CEO Chat” by Zacks Small-Cap Research Analyst on June 20th
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
From Bone Biologics Corporation
Via Business Wire
News headline image
Bone Biologics Announces 1-for-8 Reverse Stock Split
From Bone Biologics Corporation
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.